Description_x000D_ Application_x000D_ T863 has been used as a diglyceride acyltransferase (DGAT1) inhibitor:_x000D_ • to provide the opportunity to precisely control the DGAT inhibition_x000D_ • to treat mouse embryonic fibroblasts (MEFs) to analyse lipid droplet biogenesis_x000D_ • to specifically block neutral lipid synthesis and lipid droplet formation in HT-1080 cells_x000D_ • to block lipid droplet (LD) formation_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ T863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.